Therapeutic Response
PD-L1 >= 50%, Wild type ALK, and Wild type EGFR status confers therapeutic sensitivity to Carboplatin in combination with Pemetrexed and Tislelizumab in patients with Non-Small Cell Lung Cancer.
Statements
| Source and description |
|---|
PD-L1 >= 50%, Wild type ALK, and Wild type EGFR status confers therapeutic sensitivity to Carboplatin in combination with Pemetrexed and Tislelizumab in patients with Non-Small Cell Lung Cancer.
| Source and description |
|---|